bioRxiv Science⌕ Search

Biology subjects

Tagmose, L.

Publications and source records attributed to Tagmose, L..

2 recordsLinked to original sources

De novo design of small cyclic peptide inhibitors from non-canonical amino acids by cofolding-guided search

Cyclic peptides can engage targets beyond the reach of small molecules, but their discovery typically relies on libraries reused across targets, diversification around a known interaction motif, or computational methods limited to a handful of non-canonical building blocks. Here, we present nCycle-Forge, a simulated annealing framework that designs cyclic peptide binders by iteratively substituting building blocks and scoring each proposal by cofolding with the target. We designed, synthesized, and screened 1,472 cyclic peptides against the active-site pocket of Thrombin and the shallow p53-binding surface of MDM2 from the target sequence alone and without fixing binding mo-tifs. The library yielded chemically diverse hits against both targets in a single round without experimental optimization, with hit rates comparable to or up to 24-fold higher than in larger experimental libraries. Purified designs reached sub- to low-micromolar potency, with the best Thrombin inhibitor at Ki 0.14 M and the best MDM2 binder at EC50 2.4 M. Surface plasmon resonance confirmed direct binding, competition with or-thosteric inhibitors at both sites, and weaker binding under conditions expected to linearize the designs. nCycle-Forge requires no building block-specific parameterization, conformer generation, or retraining, and provides a target-focused route to functional cyclic peptides beyond the canonical amino acid alphabet.

bioinformatics↗

Apo and ligand-bound high resolution Cryo-EM structures of the human Kv3.1 reveal a novel binding site for positive modulators

Kv3 ion-channels constitute a class of functionally distinct voltage gated ion channels characterized by their ability to fire at a high frequency. Several disease relevant mutants, together with biological data, suggest the importance of this class of ion channels as drug targets for CNS disorders, and several drug discovery efforts have been reported. Despite the increasing interest for this class of ion channels, no structure of a Kv3 channel has been reported yet. We have determined the cryo-EM structure of Kv3.1 at 2.6 [A] resolution using full length wild type protein. When compared to known structures for potassium channels from other classes, a novel domain organization is observed with the cytoplasmic T1 domain, containing a well resolved Zinc site and displaying a rotation by 35{degrees}. This suggests a distinct cytoplasmic regulation mechanism for the Kv3.1 channel. A high resolution structure was obtained for Kv3.1 in complex with a novel positive modulator Lu AG00563. The structure reveals a novel ligand binding site for the Kv class of ion channels located between the voltage sensory domain and the channel pore, a region which constitutes a hotspot for disease causing mutations. The discovery of a novel binding site for a positive modulator of a voltage gated potassium channel could shed light on the mechanism of action for these small molecule potentiators. This finding could enable structure-based drug design on these targets with high therapeutic potential for the treatment of multiple CNS disorders.

biochemistry↗